Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2012 (2012), Article ID 141240, 15 pages
http://dx.doi.org/10.1100/2012/141240
Research Article

Plasmalogens Inhibit APP Processing by Directly Affecting γ-Secretase Activity in Alzheimer’s Disease

1Experimental Neurology, Saarland University, Kirrbergerstraβe, 66421 Homburg/Saar, Germany
2Psychiatry, Saarland University, Kirrbergerstraβe, 66421 Homburg/Saar, Germany
3Deutsches Institut für DemenzPrävention (DIDP), Universität des Saarlandes, Kirrbergerstraβe, 66421 Homburg/Saar, Germany
4Neurodegeneration and Neurobiology, Saarland University, Kirrbergerstraβe, 66421 Homburg/Saar, Germany

Received 10 October 2011; Accepted 30 November 2011

Academic Editor: Dietmar R. Thal

Copyright © 2012 Tatjana L. Rothhaar et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. A. Horrocks and M. Sharma, “Plasmalogen and O-alkyl glycerophospholipids,” in Phospholipids, J. N. Hawthorne and G. B. Answell, Eds., pp. 51–93, Elsevier, Amsterdam, The Netherlands, 1982. View at Google Scholar
  2. R. W. Gross, “Identification of plasmalogen as the major phospholipid constituent of cardiac sarcoplasmic reticulum,” Biochemistry, vol. 24, no. 7, pp. 1662–1668, 1985. View at Google Scholar · View at Scopus
  3. A. A. Farooqui and L. A. Horrocks, “Plasmalogens: workhorse lipids of membranes in normal and injured neurons and glia,” Neuroscientist, vol. 7, no. 3, pp. 232–245, 2001. View at Google Scholar · View at Scopus
  4. R. A. Zoeller, O. H. Morand, and C. R. Raetz, “A possible role for plasmalogens in protecting animal cells against photosensitized killing,” Journal of Biological Chemistry, vol. 263, no. 23, pp. 11590–11596, 1988. View at Google Scholar · View at Scopus
  5. W. C. Breckenridge, I. G. Morgan, J. P. Zanetta, and G. Vincendon, “Adult rat brain synaptic vesicles. II. Lipid composition,” Biochimica et Biophysica Acta, vol. 320, no. 3, pp. 681–686, 1973. View at Google Scholar · View at Scopus
  6. P. E. Glaser and R. W. Gross, “Plasmenylethanolamine facilitates rapid membrane fusion: a stopped-flow kinetic investigation correlating the propensity of a major plasma membrane constituent to adopt an HII phase with its ability to promote membrane fusion,” Biochemistry, vol. 33, no. 19, pp. 5805–5812, 1994. View at Google Scholar · View at Scopus
  7. D. A. Ford and C. C. Hale, “Plasmalogen and anionic phospholipid dependence of the cardiac sarcolemmal sodium-calcium exchanger,” FEBS Letters, vol. 394, no. 1, pp. 99–102, 1996. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Duhm, B. Engelmann, U. M. Schonthier, and S. Streich, “Accelerated maximal velocity of the red blood cell Na+/K+ pump in hyperlipidemia is related to increase in 1-palmitoyl, 2-arachidonoyl-plasmalogen phosphatidylethanolamine,” Biochimica et Biophysica Acta, vol. 1149, no. 1, pp. 185–188, 1993. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Young, P. W. Gean, L. C. Chiou, and Y. Z. Shen, “Docosahexaenoic acid inhibits synaptic transmission and epileptiform activity in the rat hippocampus,” Synapse, vol. 37, no. 2, pp. 90–94, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Nagan, A. K. Hajra, L. K. Larkins et al., “Isolation of a Chinese hamster fibroblast variant defective in dihydroxyacetonephosphate acyltransferase activity and plasmalogen biosynthesis: use of a novel two-step selection protocol,” Biochemical Journal, vol. 332, part 1, pp. 273–279, 1998. View at Google Scholar · View at Scopus
  11. H. Mandel, R. Sharf, M. Berant, R. J. Wanders, P. Vreken, and M. Aviram, “Plasmalogen phospholipids are involved in HDL-mediated cholesterol efflux: insights from investigations with plasmalogen-deficient cells,” Biochemical and Biophysical Research Communications, vol. 250, no. 2, pp. 369–373, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. A. A. Farooqui and L. A. Horrocks, “Plasmalogens, phospholipase A2, and docosahexaenoic acid turnover in brain tissue,” Journal of Molecular Neuroscience, vol. 16, no. 2-3, pp. 263–272, 2001. View at Publisher · View at Google Scholar · View at Scopus
  13. A. A. Farooqui, T. A. Rosenberger, and L. A. Horrocks, “Arachidonic acid, neurotrauma, and neurodegenerative diseases,” in Handbook of Essential Fatty Acid Biology, S. Yehuda and D. I. Mostofsky, Eds., pp. 277–296, Humana Press, Totowa, NJ, USA, 1997. View at Google Scholar
  14. H. C. Yang, A. A. Farooqui, and L. A. Horrocks, “Plasmalogen-selective phospholipase A2 and its role in signal transduction,” Journal of Lipid Mediators and Cell Signalling, vol. 14, no. 1–3, pp. 9–13, 1996. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Ginsberg, S. Rafique, J. H. Xuereb, S. I. Rapoport, and N. L. Gershfeld, “Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer's disease brain,” Brain Research, vol. 698, no. 1-2, pp. 223–226, 1995. View at Publisher · View at Google Scholar · View at Scopus
  16. K. Wells, A. A. Farooqui, L. Liss, and L. A. Horrocks, “Neural membrane phospholipids in Alzheimer disease,” Neurochemical Research, vol. 20, no. 11, pp. 1329–1333, 1995. View at Publisher · View at Google Scholar · View at Scopus
  17. Z. Guan, Y. Wang, N. J. Cairns, P. L. Lantos, G. Dallner, and P. J. Sindelar, “Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease,” Journal of Neuropathology and Experimental Neurology, vol. 58, no. 7, pp. 740–747, 1999. View at Google Scholar · View at Scopus
  18. P. Demediuk, R. D. Saunders, and D. K. Anderson, “Membrane lipid changes in laminectomized and traumatized cat spinal cord,” Proceedings of the National Academy of Sciences of the United States of America, vol. 82, no. 20, pp. 7071–7075, 1985. View at Google Scholar · View at Scopus
  19. P. Viani, I. Zini, G. Cervato, G. Biagini, L. F. Agnati, and B. Cestaro, “Effect of endothelin-1 induced ischemia on peroxidative damage and membrane properties in rat striatum synaptosomes,” Neurochemical Research, vol. 20, no. 6, pp. 689–695, 1995. View at Publisher · View at Google Scholar · View at Scopus
  20. J. P. Zhang and G. Y. Sun, “Free fatty acids, neutral glycerides, and phosphoglycerides in transient focal cerebral ischemia,” Journal of Neurochemistry, vol. 64, no. 4, pp. 1688–1695, 1995. View at Google Scholar · View at Scopus
  21. S. Schedin, P. J. Sindelar, P. Pentchev, U. Brunk, and G. Dallner, “Peroxisomal impairment in Niemann-Pick type C disease,” Journal of Biological Chemistry, vol. 272, no. 10, pp. 6245–6251, 1997. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Yanagihara and J. N. Cumings, “Alterations of phospholipids, particularly plasmalogens, in the demyelination of multiple sclerosis as compared with that of cerebral oedema,” Brain, vol. 92, no. 1, pp. 59–70, 1969. View at Publisher · View at Google Scholar · View at Scopus
  23. A. A. Farooqui, S. I. Rapoport, and L. A. Horrocks, “Membrane phospholipid alterations in Alzheimer's disease: deficiency of ethanolamine plasmalogens,” Neurochemical Research, vol. 22, no. 4, pp. 523–527, 1997. View at Google Scholar · View at Scopus
  24. X. Han, D. M. Holtzman, and D. W. McKeel Jr., “Plasmalogen deficiency in early Alzheimer's disease subjects and in animal models: molecular characterization using electrospray ionization mass spectrometry,” Journal of Neurochemistry, vol. 77, no. 4, pp. 1168–1180, 2001. View at Publisher · View at Google Scholar · View at Scopus
  25. J. W. Pettegrew, K. Panchalingam, R. L. Hamilton, and R. J. Mcclure, “Brain membrane phospholipid alterations in Alzheimer's disease,” Neurochemical Research, vol. 26, no. 7, pp. 771–782, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. C. L. Masters, G. Simms, and N. A. Weinman, “Amyloid plaque core protein in Alzheimer disease and Down syndrome,” Proceedings of the National Academy of Sciences of the United States of America, vol. 82, no. 12, pp. 4245–4249, 1985. View at Google Scholar
  27. D. J. Selkoe, “Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases,” Nature Cell Biology, vol. 6, no. 11, pp. 1054–1061, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Haass, “Take five—BACE and the γ-secretase quartet conduct Alzheimer's amyloid β-peptide generation,” EMBO Journal, vol. 23, no. 3, pp. 483–488, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Sinha, J. P. Anderson, R. Barbour et al., “Purification and cloning of amyloid precursor protein β-secretase from human brain,” Nature, vol. 402, no. 6761, pp. 537–540, 1999. View at Publisher · View at Google Scholar · View at Scopus
  30. H. Steiner, R. Fluhrer, and C. Haass, “Intramembrane proteolysis by γ-secretase,” Journal of Biological Chemistry, vol. 283, no. 44, pp. 29627–29631, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Wakabayashi and B. De Strooper, “Presenilins: members of the γ-secretase quartets, but part-time soloists too,” Physiology, vol. 23, no. 4, pp. 194–204, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. J. D. Buxbaum, K. N. Liu, Y. Luo et al., “Evidence that tumor necrosis factor α converting enzyme is involved in regulated α-secretase cleavage of the Alzheimer amyloid protein precursor,” Journal of Biological Chemistry, vol. 273, no. 43, pp. 27765–27767, 1998. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Lammich, E. Kojro, R. Postina et al., “Constitutive and regulated α-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloprotease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 7, pp. 3922–3927, 1999. View at Publisher · View at Google Scholar · View at Scopus
  34. H. Koike, S. Tomioka, H. Sorimachi et al., “Membrane-anchored metalloprotease MDC9 has an α-secretase activity responsible for processing the amyloid precursor protein,” Biochemical Journal, vol. 343, part 2, pp. 371–375, 1999. View at Publisher · View at Google Scholar · View at Scopus
  35. T. M. Allinson, E. T. Parkin, A. J. Turner, and N. M. Hooper, “ADAMs family members as amyloid precursor protein α-secretases,” Journal of Neuroscience Research, vol. 74, no. 3, pp. 342–352, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. H. Braak and E. Braak, “Neuropathological stageing of Alzheimer-related changes,” Acta Neuropathologica, vol. 82, no. 4, pp. 239–259, 1991. View at Google Scholar · View at Scopus
  37. P. K. Smith, R. I. Krohn, G. T. Hermanson et al., “Measurement of protein using bicinchoninic acid,” Analytical Biochemistry, vol. 150, no. 1, pp. 76–85, 1985. View at Google Scholar
  38. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method,” Methods, vol. 25, no. 4, pp. 402–408, 2001. View at Google Scholar
  39. M. O. Grimm, J. Kuchenbecker, T. L. Rothhaar et al., “Plasmalogen synthesis is regulated via alkyl-dihydroxyacetonephosphate-synthase by amyloid precursor protein processing and is affected in Alzheimer's disease,” Journal of Neurochemistry, vol. 116, no. 5, pp. 916–925, 2011. View at Publisher · View at Google Scholar
  40. M. O. Grimm, S. Grösgen, M. Riemenschneider, H. Tanila, H. S. Grimm, and T. Hartmann, “From brain to food: analysis of phosphatidylcholins, lyso-phosphatidylcholins and phosphatidylcholin-plasmalogens derivates in Alzheimer's disease human post mortem brains and mice model via mass spectrometry,” Journal of Chromatography A, vol. 1218, no. 42, pp. 7713–7722, 2011. View at Publisher · View at Google Scholar
  41. M. O. Grimm, H. S. Grimm, I. Tomic, K. Beyreuther, T. Hartmann, and C. Bergmann, “Independent inhibition of Alzheimer disease β- and γ-secretase cleavage by lowered cholesterol levels,” Journal of Biological Chemistry, vol. 283, no. 17, pp. 11302–11311, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. M. O. Grimm, J. Kuchenbecker, S. Grösgen et al., “Docosahexaenoic acid reduces amyloid β production via multiple pleiotropic mechanisms,” Journal of Biological Chemistry, vol. 286, no. 16, pp. 14028–14039, 2011. View at Publisher · View at Google Scholar
  43. T. M. Allinson, E. T. Parkin, T. P. Condon et al., “The role of ADAM10 and ADAM17 in the ectodomain shedding of angiotensin converting enzyme and the amyloid precursor protein,” European Journal of Biochemistry, vol. 271, no. 12, pp. 2539–2547, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. T. Miyazawa, S. Kanno, T. Eitsuka, and K. Nakagawa, “Plasmalogen: a short review ans newly-discovered functions,” in Dietary Fats and Risk of Chronic Disease, Y. Yanagita, H. R. Knapp,, and Y. S. Huang, Eds., pp. 196–202, AOCS Publishing, 2006. View at Google Scholar
  45. A. A. Spector and M. A. Yorek, “Membrane lipid composition and cellular function,” Journal of Lipid Research, vol. 26, no. 9, pp. 1015–1035, 1985. View at Google Scholar · View at Scopus
  46. M. R. Prasad, M. A. Lovell, M. Yatin, H. Dhillon, and W. R. Markesbery, “Regional membrane phospholipid alterations in Alzheimer's disease,” Neurochemical Research, vol. 23, no. 1, pp. 81–88, 1998. View at Publisher · View at Google Scholar · View at Scopus
  47. D. B. Goodenowe, L. L. Cook, J. Liu et al., “Peripheral ethanolamine plasmalogen deficiency: a logical causative factor in Alzheimer's disease and dementia,” Journal of Lipid Research, vol. 48, no. 11, pp. 2485–2498, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. P. L. Wood, R. Mankidy, S. Ritchie et al., “Circulating plasmalogen levels and Alzheimer disease assessment scale-cognitive scores in Alzheimer patients,” Journal of Psychiatry and Neuroscience, vol. 35, no. 1, pp. 59–62, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. N. Fabelo, V. Martin, G. Santpere et al., “Severe alterations in lipid composition of frontal cortex lipid rafts from Parkinson's disease and incidental Parkinson's disease,” Molecular Medicine, vol. 17, no. 9-10, pp. 1107–1118, 2011. View at Publisher · View at Google Scholar
  50. Y. Tamai, H. Kojima, F. Ikuta, and T. Kumanishi, “Alterations in the composition of brain lipids in patients with Creutzfeldt-Jakob disease,” Journal of the Neurological Sciences, vol. 35, no. 1, pp. 59–76, 1978. View at Publisher · View at Google Scholar · View at Scopus
  51. A. Federico, P. Annunziata, and G. Malentacchi, “Neurochemical changes in Creutzfeldt-Jakob disease,” Journal of Neurology, vol. 223, no. 2, pp. 135–146, 1980. View at Google Scholar · View at Scopus
  52. L. K. Hein, S. Duplock, J. J. Hopwood, and M. Fuller, “Lipid composition of microdomains is altered in a cell model of Gaucher disease,” Journal of Lipid Research, vol. 49, no. 8, pp. 1725–1734, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. I. Hozumi, M. Nishizawa, T. Ariga, and T. Miyatake, “Biochemical and clinical analysis of accumulated glycolipids in symptomatic heterozygotes of angiokeratoma corporis diffusum (Fabry's disease) in comparison with hemizygotes,” Journal of Lipid Research, vol. 31, no. 2, pp. 335–340, 1990. View at Google Scholar · View at Scopus
  54. K. Maalouf, J. Jia, S. Rizk et al., “A modified lipid composition in Fabry disease leads to an intracellular block of the detergent-resistant membrane-associated dipeptidyl peptidase IV,” Journal of Inherited Metabolic Disease, vol. 33, no. 4, pp. 445–449, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. K. Fassbender, M. Simons, C. Bergmann et al., “Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 98, no. 10, pp. 5856–5861, 2001. View at Publisher · View at Google Scholar · View at Scopus
  56. Q. Zha, Y. Ruan, T. Hartmann, K. Beyreuther, and D. Zhang, “GM1 ganglioside regulates the proteolysis of amyloid precursor protein,” Molecular Psychiatry, vol. 9, no. 10, pp. 946–952, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. B. Wolozin, “Cholesterol and the biology of Alzheimer's disease,” Neuron, vol. 41, no. 1, pp. 7–10, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. M. O. Grimm, H. S. Grimm, A. J. Patzold et al., “Regulation of cholesterol and sphingomyelin metabolism by amyloid-β and presenilin,” Nature Cell Biology, vol. 7, no. 11, pp. 1118–1123, 2005. View at Publisher · View at Google Scholar
  59. K. Furukawa, B. L. Sopher, R. E. Rydel et al., “Increased activity-regulating and neuroprotective efficacy of α-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain,” Journal of Neurochemistry, vol. 67, no. 5, pp. 1882–1896, 1996. View at Google Scholar · View at Scopus
  60. H. Meziane, J. C. Dodart, C. Mathis et al., “Memory-enhancing effects of secreted forms of the β-amyloid precursor protein in normal and amnestic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 21, pp. 12683–12688, 1998. View at Publisher · View at Google Scholar · View at Scopus
  61. M. P. Mattson, Z. H. Guo, and J. D. Geiger, “Secreted form of amyloid precursor protein enhances basal glucose and glutamate transport and protects against oxidative impairment of glucose and glutamate transport in synaptosomes by a cyclic GMP-mediated mechanism,” Journal of Neurochemistry, vol. 73, no. 2, pp. 532–537, 1999. View at Publisher · View at Google Scholar · View at Scopus
  62. R. C. von Rotz, B. M. Kohli, J. Bosset et al., “The APP intracellular domain forms nuclear multiprotein complexes and regulates the transcription of its own precursor,” Journal of Cell Science, vol. 117, no. 19, pp. 4435–4448, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. M. O. Grimm, S. Grösgen, T. L. Rothhaar et al., “Intracellular APP domain regulates serine-palmitoyl-CoA transferase expression and is affected in alzheimer's disease,” International Journal of Alzheimer's Disease, Article ID 695413, 2011. View at Publisher · View at Google Scholar
  64. M. Blacker, M. C. Noe, T. J. Carty, C. G. Goodyer, and A. C. LeBlanc, “Effect of tumor necrosis factor-α converting enzyme (TACE) and metalloprotease inhibitor on amyloid precursor protein metabolism in human neurons,” Journal of Neurochemistry, vol. 83, no. 6, pp. 1349–1357, 2002. View at Publisher · View at Google Scholar · View at Scopus
  65. I. Karkkainen, E. Rybnikova, M. Pelto-Huikko, and A. P. Huovila, “Metalloprotease-disintegrin (ADAM) genes are widely and differentially expressed in the adult CNS,” Molecular and Cellular Neurosciences, vol. 15, no. 6, pp. 547–560, 2000. View at Publisher · View at Google Scholar · View at Scopus
  66. E. Llano, G. Adam, A. M. Pendas et al., “Structural and enzymatic characterization of Drosophila Dm2-MMP, a membrane-bound matrix metalloproteinase with tissue-specific expression,” Journal of Biological Chemistry, vol. 277, no. 26, pp. 23321–23329, 2002. View at Publisher · View at Google Scholar
  67. J. Lin, X. Yan, A. Markus, C. Redies, A. Rolfs, and J. Luo, “Expression of seven members of the ADAM family in developing chicken spinal cord,” Developmental Dynamics, vol. 239, no. 4, pp. 1246–1254, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. X. Han, “Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer's disease,” Biochimica et Biophysica Acta, vol. 1801, no. 8, pp. 774–783, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. K. V. Subbarao, J. S. Richardson, and L. S. Ang, “Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro,” Journal of Neurochemistry, vol. 55, no. 1, pp. 342–345, 1990. View at Publisher · View at Google Scholar · View at Scopus
  70. R. J. Mark, Z. Pang, J. W. Geddes, K. Uchida, and M. P. Mattson, “Amyloid β-peptide impairs glucose transport in hippocampal and cortical neurons: involvement of membrane lipid peroxidation,” Journal of Neuroscience, vol. 17, no. 3, pp. 1046–1054, 1997. View at Google Scholar · View at Scopus
  71. W. R. Markesbery, “Oxidative stress hypothesis in Alzheimer's disease,” Free Radical Biology and Medicine, vol. 23, no. 1, pp. 134–147, 1997. View at Publisher · View at Google Scholar · View at Scopus
  72. S. M. Yatin, S. Varadarajan, C.D. Link, and D. A. Butterfield, “In vitro and in vivo oxidative stress associated with Alzheimer's amyloid beta-peptide (1–42),” Neurobiol Aging, vol. 20, no. 3, pp. 325–330, 1999. View at Google Scholar
  73. D. A. Butterfield and C. M. Lauderback, “Lipid peroxidation and protein oxidation in Alzheimer's disease brain: potential causes and consequences involving amyloid β-peptide-associated free radical oxidative stress,” Free Radical Biology and Medicine, vol. 32, no. 11, pp. 1050–1060, 2002. View at Publisher · View at Google Scholar · View at Scopus
  74. H. Mohmmad Abdul, G. L. Wenk, M. Gramling, B. Hauss-Wegrzyniak, and D. A. Butterfield, “APP and PS-1 mutations induce brain oxidative stress independent of dietary cholesterol: implications for Alzheimer's disease,” Neuroscience Letters, vol. 368, no. 2, pp. 148–150, 2004. View at Publisher · View at Google Scholar · View at Scopus
  75. R. O. Sanchez-Mejia, J. W. Newman, S. Toh et al., “Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease,” Nature Neuroscience, vol. 11, no. 11, pp. 1311–1318, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. R. O. Sanchez-Mejia and L. Mucke, “Phospholipase A2 and arachidonic acid in Alzheimer's disease,” Biochimica et Biophysica Acta, vol. 1801, no. 8, pp. 784–790, 2010. View at Publisher · View at Google Scholar · View at Scopus